Effects of a growth hormone receptor antagonist on bone markers in acromegaly

被引:31
作者
Fairfield, WP
Sesmilo, G
Katznelson, L
Pulaski, K
Freda, PU
Stavrou, S
Kleinberg, D
Klibanski, A
机构
[1] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Hosp Clin Barcelona, Serv Endocrinol, Barcelona, Spain
[4] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[5] Univ Med Ctr, New York, NY USA
关键词
D O I
10.1046/j.1365-2265.2002.01624.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Excess GH secretion, as occurs in acromegaly, is associated with abnormalities in bone turnover markers and bone mineral density (BMD). GH administration in GH deficient patients causes an increase in bone turnover. IGF-I mediates many of the metabolic actions of GH, although GH may have direct effects upon bone. In patients with acromegaly who are treated with a GH receptor antagonist, selective blockade of the GH receptor results in a decrease in circulating IGF-I levels in the majority of cases. We hypothesized that, in acromegaly, antagonism of GH receptors would result in a decrease in serum markers of bone turnover, including serum procollagen I carboxy-terminal propeptide (PICP), osteocalcin and N-telopeptide (NTx). DESIGN AND SUBJECTS Twenty-seven patients with acromegaly were enrolled as part of a multicentre 12-week trial of a GH receptor antagonist and were randomized to placebo (n = 7) or 10, 15 or 20 mg of pegvisomant (n = 20). MEASUREMENTS Serum markers of bone turnover were determined at baseline and 12 weeks. RESULTS Baseline bone turnover markers were above the upper limit of normal in 23%, 19% and 32% of subjects for osteocalcin, PICP and NTx, respectively. During the 12-week placebo-controlled period, there were significant decreases in serum markers of bone formation, osteocalcin (-2.2 +/- 0.44 vs. placebo +0.01 +/- 0.39 nmol/l, P = 0.009) and PICP (-23.6 +/- 9.6 vs. placebo +18.1 +/- 12.8 mug/l, P = 0.022) and a serum marker of bone resorption, NTx (-4.4 +/- 1.4, placebo +1.0 +/- 0.3 nm, P = 0.024). CONCLUSIONS Using a specific GH receptor antagonist, we found that normalization of IGF-I is associated with rapid reductions in markers of both bone formation and resorption, and that these processes remain coupled. These data confirm the highly significant effects of GH and IGF-I in modulating bone turnover. The independent contributions of GH and IGF-I to these effects and the long-term effects on BMD in this population remain to be determined.
引用
收藏
页码:385 / 390
页数:6
相关论文
共 23 条
  • [1] Effects of short-term calcium depletion and repletion on biochemical markers of bone turnover in young adult women
    Åkesson, K
    Lau, KHW
    Johnston, P
    Imperio, E
    Baylink, DJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (06) : 1921 - 1927
  • [2] Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency - A randomized, placebo-controlled trial
    Baum, HBA
    Biller, BMK
    Finkelstein, JS
    Cannistraro, KB
    Oppenheim, DS
    Schoenfeld, AD
    Michel, TH
    Wittink, H
    Klibanski, A
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 125 (11) : 883 - +
  • [3] ABNORMAL BODY-COMPOSITION AND REDUCED BONE MASS IN GROWTH-HORMONE DEFICIENT HYPOPITUITARY ADULTS
    BESHYAH, SA
    FREEMANTLE, C
    THOMAS, E
    RUTHERFORD, O
    PAGE, B
    MURPHY, M
    JOHNSTON, DG
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 42 (02) : 179 - 189
  • [4] Bone metabolism in endurance trained athletes: A comparison to population-based controls based on DXA, SXA, quantitative ultrasound, and biochemical markers
    Brahm, H
    Strom, H
    PiehlAulin, K
    Mallmin, H
    Ljunghall, S
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (06) : 448 - 454
  • [5] CORRELATION AMONG PLASMA OSTEOCALCIN, GROWTH-HORMONE, AND SOMATOMEDIN-C IN ACROMEGALY
    DELAPIEDRA, C
    CARBO, E
    LARRANAGA, J
    CASTRO, N
    HORCAJADA, C
    RAPADO, A
    POMBO, JLH
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1988, 43 (01) : 44 - 45
  • [6] GROWTH-HORMONE DEPENDENT STIMULATION OF OSTEOBLAST-LIKE CELLS IN SERUM-FREE CULTURES VIA LOCAL SYNTHESIS OF INSULIN-LIKE GROWTH FACTOR-I
    ERNST, M
    FROESCH, ER
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 151 (01) : 142 - 147
  • [7] RATIONAL DESIGN OF POTENT ANTAGONISTS TO THE HUMAN GROWTH-HORMONE RECEPTOR
    FUH, G
    CUNNINGHAM, BC
    FUKUNAGA, R
    NAGATA, S
    GOEDDEL, DV
    WELLS, JA
    [J]. SCIENCE, 1992, 256 (5064) : 1677 - 1680
  • [8] REDUCED BONE-MINERAL DENSITY IN PATIENTS WITH ADULT-ONSET GROWTH-HORMONE DEFICIENCY
    HOLMES, SJ
    ECONOMOU, G
    WHITEHOUSE, RW
    ADAMS, JE
    SHALET, SM
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (03) : 669 - 674
  • [9] Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency
    Johannsson, G
    Rosen, T
    Bosaeus, I
    Sjostrom, L
    Bengtsson, BA
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (08) : 2865 - 2873
  • [10] GROWTH-HORMONE STIMULATES PROLIFERATION AND DIFFERENTIATION OF NORMAL HUMAN OSTEOBLAST-LIKE CELLS-INVITRO
    KASSEM, M
    BLUM, W
    RISTELI, J
    MOSEKILDE, L
    ERIKSEN, EF
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1993, 52 (03) : 222 - 226